Knowledge Hubs
The latest news on genitourinary oncological disease states.
Prostate Cancer Knowledge Hubs
Advertisement
Urothelial Carcinoma Knowledge Hubs
Testicular, Penile, and Rare Malignancies Knowledge Hubs
Roundtable Discussions
The panel concludes with thoughts on the evolving role of lutetium-177 in metastatic castration-resistant prostate cancer.
The panel explores ARANOTE, ARASENS, and PEACE-1, emphasizing drug tolerability, toxicity trade-offs, and more.
The panel breaks down the growing role of MDT and the evolving use of radiation in oligometastatic disease.
The panel considers the ARANOTE trial of darolutamide, emphasizing its tolerability and broad eligibility criteria.
The panel examines the nuances of selecting triplet vs doublet therapy for patients with high-volume or high-risk disease.
The panel discusses how PSMA PET imaging is changing disease classification and decision-making.
Advertisement
Advertisement
Editorial Advisory Board
Brian Rini, MD, FASCOEditor | Chief of Clinical Trials at Vanderbilt-Ingram Cancer Center
Thomas Powles, MBBS, MRCP, MDEditor | Director, Barts Cancer Centre at St. Bartholomew's Hospital
Catherine H. Marshall, MD, MPHEditor | Assistant Professor of Oncology at the Johns Hopkins University School of Medicine
Jérémie Calais, MD, PhDEditor | Director of the Theranostics and Clinical Research Programs at the University of California, Los Angeles
Akhil Abraham Saji, MDEditor | Urologist at Swedish Health Services
David Ambinder, MDEditor | Urology Resident at New York Medical College/Westchester Medical Center
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.